PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Annex 1, Sterility Assurance, and the Rising Bar for PUPSIT

The latest revision of EU GMP Annex 1 has transformed sterile manufacturing expectations from a primarily reactive, end-of-line mindset into a fully integrated approach to contamination control and sterility assurance. Among the changes drawing the most attention from sterile f ill/finish teams is the clarified expectation for pre-use post-sterilisation integrity testing (PUPSIT) of sterilising grade filters.

PUPSIT is now widely viewed by EU regulators as a standard element of a compliant sterile filtration strategy rather than a discretionary add-on. For sponsors targeting EU approval, or planning eventual global expansion that includes Europe, it has become a practical “cost of admission” alongside isolator technology, robust environmental monitoring, and formal contamination control strategies.

What PUPSIT Actually Addresses

At its core, PUPSIT is a response to a simple but significant risk: a sterilising filter that appears to pass post-use integrity testing may in fact have been compromised prior to, or during, product filtration. Damage introduced during transport, handling, assembly, or sterilisation can be partially masked by product fouling of the membrane during processing. In these cases, a defective filter can meet post-use integrity limits because the product reduces f low through what is no longer a fully integral membrane.

PUPSIT mitigates that risk by verifying filter integrity after sterilisation but immediately prior to sterile filtration. In practice, operators wet the sterilising filter with a suitable medium – commonly water, buffer, or product, depending on filter design, validation data, and product characteristics – and connect a test instrument to conduct an automated integrity test. Parameters such as pressure, hold time, and acceptable test limits are established during filter and process validation. The outcome is a quantitative integrity readout with a pass/fail result before any product is exposed to the filter.

From a sterility assurance standpoint, this sequencing is critical. An integral filter at the time of actual use is a much stronger control than a filter only proven integral after product has already passed through.

Regulatory Expectations and When PUPSIT May Be Omitted

Annex 1 states that “the integrity of sterilised filter assembly should be verified by integrity testing before use (PUPSIT),” and in regulatory practice this “should” is treated as a default expectation. By contrast, the U.S. FDA has not made PUPSIT mandatory, which means global programmes must reconcile differing expectations when designing a single filtration strategy for multiple markets.

For products intended for the EU, omitting PUPSIT requires more than a procedural preference; it demands a robust, documented risk assessment that convinces regulators the likelihood of masked damage is acceptably low. Such an assessment typically examines:

• Filter type, manufacturer, and manufacturing method.

• Transportation, storage, and sterilisation methods.

• Packaging, handling, and inspection procedures.

• Product type, including potential for membrane fouling or masking defects.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026